68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.
April 2016 in “Journal of Investigative Dermatology” In this study, three patients with extensive alopecia areata receiving ustekinumab treatment showed significant hair regrowth and decreased inflammation over 20 weeks, suggesting potential targeted treatment for this condition.
25 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.
53 citations
,
July 2009 in “Cancer Research” In this mouse study, the researchers found that the monoclonal antibody ME1 causes hair follicle inflammation by up-regulating TNFα, which can be reduced by TNFα and interleukin-1 inhibitors.
May 2025 in “Experimental Dermatology” This study found that specific TRPM5 modulators are unlikely to directly affect sebaceous glands, but safe TPPO analogues may provide moderate lipogenic and anti-inflammatory effects beneficial for dry skin conditions.